CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $243.21M, lower than 95% of all stocks globally
- PositionCurrent ratio is 34.33×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
243.21MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.00xvs all stocks
52-Week Change
-48.59%vs all stocks
Market Capitalization
243.21MUSDvs all stocks (USD)
Enterprise Value
-90.23MUSDvs all stocks (USD)
Forward P/E
-6.03xvs Biotechnology peers
Price to Book (MRQ)
0.6994xvs Biotechnology peers
Enterprise to EBITDA
1.06xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-18.36%vs Biotechnology peers
Return on Equity (TTM)
-27.10%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
-56.78MUSDvs all stocks (USD)
EBITDA (TTM)
-85.18MUSDvs all stocks (USD)
Net Income (TTM)
-76.12MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-63.56MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-37.74MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-84.77MUSDvs all stocks (USD)
Pre-tax Income
-74.88MUSDFY2025 · Dec 31, 2025Net Income
-74.88MUSDFY2025 · Dec 31, 2025EBIT
-84.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-83.38MUSDFY2025 · Dec 31, 2025Research & Development
56.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
28.67MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-59.77MUSDFY2025 · Dec 31, 2025Free Cash Flow
-60.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
198.73MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.47MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.10MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
428.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.27MUSDFY2025 · Dec 31, 2025Capital Expenditures
-314.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-180.22MUSDFY2025 · Dec 31, 2025Sale of Investments
211.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
30.72MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
164.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
66.61MSharesUpdated Jul 18, 2026Float Shares
36.74MSharesUpdated Jul 18, 2026Shares Short
6.43MSharesUpdated Jul 18, 2026Short Ratio
1.21daysvs all stocks
Short % of Shares Outstanding
9.76%vs all stocks
% Held by Insiders
3.83%vs all stocks
% Held by Institutions
126.06%vs all stocks
Total Cash (MRQ)
333.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.00USDUpdated Jul 18, 2026Total Debt (MRQ)
5.87MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0176xvs Biotechnology peers
Current Ratio (MRQ)
34.33xvs Biotechnology peers
Book Value per Share (MRQ)
5.00USDUpdated Jul 18, 2026Total Assets
366.28MUSDvs all stocks (USD)
Total Current Assets
357.48MUSDFY2025 · Dec 31, 2025Total Liabilities
17.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.80MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.24MUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.05MUSDFY2025 · Dec 31, 2025Cash Equivalents
197.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
197.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
154.77MUSDFY2025 · Dec 31, 2025Accounts Payable
1.59MUSDFY2025 · Dec 31, 2025Short-term Debt
2.40MUSDFY2025 · Dec 31, 2025Other Current Liabilities
258.00KUSDFY2025 · Dec 31, 2025Long-term Debt
4.04MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
197.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
67.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-594.28MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
349.00MUSDvs all stocks (USD)
52-Week Low
2.83USDUpdated Jul 18, 202652-Week High
15.74USDUpdated Jul 18, 202652-Week Change
-48.59%vs all stocks
Beta
3.00xvs all stocks
50-Day MA
4.86USDUpdated Jul 18, 2026200-Day MA
8.29USDUpdated Jul 18, 2026Avg 10-Day Volume
1.65MSharesUpdated Jul 18, 2026Avg 30-Day Volume
3.11MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.15USDUpdated Jul 18, 2026Other Income / Expense
9.89MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 34.33×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 34.33Industry median: 5.64Industry P95: 23.02Peers compared: 261
Price-to-book is 0.7×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.70Industry median: 2.97Industry P5: 1.03Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $243.21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 243,211,621Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
SuperX AI Technology Limited
6 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Jiangnan Yifan Motor Co., Ltd.
5 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Draganfly Inc.
5 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration